Clinical association between pharmacogenomics and adverse drug reactions
Version 2 2024-06-06, 04:33Version 2 2024-06-06, 04:33
Version 1 2015-05-14, 15:39Version 1 2015-05-14, 15:39
journal contribution
posted on 2024-06-06, 04:33authored byZW Zhou, XW Chen, KB Sneed, YX Yang, X Zhang, ZX He, K Chow, T Yang, Wei DuanWei Duan, SF Zhou
Adverse drug reactions (ADRs) are a major public health concern and cause significant patient morbidity and mortality. Pharmacogenomics is the study of how genetic polymorphisms affect an individual's response to pharmacotherapy at the level of a whole genome. This article updates our knowledge on how genetic polymorphisms of important genes alter the risk of ADR occurrence after an extensive literature search. To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB. At least 28 genes associated with the risk of ADRs have been listed by the Food and Drug Administration as pharmacogenomic biomarkers. With the availability of affordable and reliable testing tools, pharmacogenomics looks promising to predict, reduce, and minimize ADRs in selected populations.